Country: United States
Language: English
Source: NLM (National Library of Medicine)
DIVALPROEX SODIUM (UNII: 644VL95AO6) (VALPROIC ACID - UNII:614OI1Z5WI)
Aidarex Pharmaceuticals LLC
DIVALPROEX SODIUM
VALPROIC ACID 500 mg
ORAL
PRESCRIPTION DRUG
Divalproex sodium is a valproate and is indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. The efficacy of divalproex sodium delayed-release tablets, USP was established in 3-week trials with patients meeting DSM-III-R criteria for bipolar disorder who were hospitalized for acute mania [see Clinical Studies (14.1) ] . The safety and effectiveness of divalproex sodium delayed-release tablets, USP for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. Therefore, healthcare providers who elect to use divalproex sodium delayed-release tablets, USP for extended periods should continually re-evaluate the long-term usefulness of the drug for
Divalproex sodium delayed-release tablets, USP are supplied as: 500 mg - pink, oval-shaped tablets, debossed “2707” on one side and debossed “V” on the reverse side: Recommended storage Store tablets at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Maalox® is a registered trademark of Novartis Consumer Health, Inc. Titralac® is a registered trademark of Minnesota Mining and Manufacturing Company.
Abbreviated New Drug Application
DIVALPROEX SODIUMDELAYED-RELEASE DELAYED-RELEASE- DIVALPROEX SODIUM TABLET, FILM COATED Aidarex Pharmaceuticals LLC ---------- MEDICATION GUIDE Read this Medication Guide before you start taking divalproex sodium delayed-release tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. What is the most important information I should know about divalproex sodium delayed-release tablets? Do not stop taking divalproex sodium delayed-release tablets without first talking to your healthcare provider. Stopping divalproex sodium delayed-release tablets suddenly can cause serious problems. Divalproex sodium delayed-release tablets can cause serious side effects, including: 1. Serious liver damage that can cause death, especially in children younger than 2 years old. The risk of getting this serious liver damage is more likely to happen within the first 6 months of treatment. Call your healthcare provider right away if you get any of the following symptoms: • nausea or vomiting that does not go away • loss of appetite • pain on the right side of your stomach (abdomen) • dark urine • swelling of your face • yellowing of your skin or the whites of your eyes In some cases, liver damage may continue despite stopping the drug. 2. Divalproex sodium delayed-release tablets may harm your unborn baby. • If you take divalproex sodium delayed-release tablets during pregnancy for any medical condition, your baby is at risk for serious birth defects. The most common birth defects with divalproex sodium delayed-release tablets affect the brain and spinal cord and are called spina bifida or neural tube defects. These defects occur in 1 to 2 out of every 100 babies born to mothers who use this medicine during pregnancy. These defects can begin in the first month, even before you know you are pregnant. Other birth defects can happen. • Birth defects may occur even in children born to women Read the complete document
DIVALPROEX SODIUMDELAYED-RELEASE DELAYED-RELEASE- DIVALPROEX SODIUM TABLET, FILM COATED AIDAREX PHARMACEUTICALS LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP. DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP FOR ORAL USE INITIAL U.S. APPROVAL: 1983 WARNINGS: LIFE THREATENING ADVERSE REACTIONS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ HEPATOTOXICITY, INCLUDING FATALITIES, USUALLY DURING THE FIRST 6 MONTHS OF TREATMENT. CHILDREN UNDER THE AGE OF TWO YEARS ARE AT A CONSIDERABLY HIGHER RISK OF FATAL HEPATOTOXICITY. MONITOR PATIENTS CLOSELY, AND PERFORM LIVER FUNCTION TESTS PRIOR TO THERAPY AND AT FREQUENT INTERVALS THEREAFTER (5.1) FETAL RISK, PARTICULARLY NEURAL TUBE DEFECTS, OTHER MAJOR MALFORMATIONS, AND DECREASED IQ (5.2, 5.3, 5.4) PANCREATITIS, INCLUDING FATAL HEMORRHAGIC CASES (5.5) RECENT MAJOR CHANGES Boxed Warning, Fetal Risk 06/2013 Indications and Usage, Important Limitations (1.4) 06/2013 Contraindications (4) 06/2013 Warnings and Precautions, Birth Defects (5.2) 06/2013 Warnings and Precautions, Decreased IQ (5.3) 06/2013 Warnings and Precautions, Use in Women of Childbearing Potential (5.4) 06/2013 Warnings and Precautions, Medication Residue in the Stool (5.18) 02/2013 INDICATIONS AND USAGE Divalproex sodium delayed-release tablets, USP are antiepileptic drugs indicated for: Treatment of manic episodes associated with bipolar disorder (1.1) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1.2) Prophylaxis of migraine headaches (1.3) DOSAGE AND ADMINISTRATION Divalproex sodium delayed-release tablets are administered orally in divided doses. Divalproex sodium delayed- release tablets should be swallowed whole and shoul Read the complete document